Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 2, 2012

FDA Approves Roche's HIV Test

  • Roche’s COBAS® TaqMan® HIV-1 Test, v2.0, has been approved by the FDA. The test will be commercially available in the U.S. later this year.

    This HIV viral-load test targets two highly conserved regions of the HIV-1 genome and avoids any regions that are current drug targets. Roche says that this approach provides increased reliability as compared to other single-target assays should a mutation occur.

    “The approval of the Roche HIV test expands the availability to more laboratories, clinicians, and patients,” says Paul Brown, Ph.D., head of Roche Molecular Diagnostics. “Roche is committed to developing new diagnostic tools such as this HIV ‘dual target’ test to help improve the ability of physicians to monitor viral load and properly treat people living with HIV.”

    The COBAS TaqMan HIV-1 Test, v2.0 utilizes the FDA-approved High Pure System Viral Nucleic Acid Kit for manual specimen preparation and the COBAS TaqMan 48 analyzer for automated amplification and detection.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »